

## **Supplementary Materials**


### **Phage Display Screening of Bovine Antibodies to Foot-and-Mouth Disease Virus and Their Application in a Competitive ELISA for Serodiagnosis**

Sukyo Jeong<sup>1</sup>, Hyun Joo Ahn<sup>1</sup>, Kyung-Jin Min<sup>1</sup>, Jae-Won Byun<sup>2</sup>, Hyun Mi Pyo<sup>2</sup>, Mi-Young Park<sup>2</sup>, Bok Kyung Ku<sup>2</sup>, Jinju Nah<sup>2</sup>, Soyoon Ryoo<sup>2</sup>, Sung-Hwan Wee<sup>2</sup> and Sang Jick Kim<sup>1,\*</sup>.

<sup>1</sup> Synthetic Biology and Bioengineering Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea


<sup>2</sup> Foot-and-Mouth Disease Division, Animal and Plant Quarantine Agency, Gyongsangbuk-do 39660, Korea

**Figure S1. Expression and purification of scFv-Fcs using HEK293E cells.** 12% SDS-PAGE analysis of the purified scFv-Fcs by affinity chromatography using Protein G-agarose resin. All the scFv-Fcs were detected at the predicted molecular weight of around 55 kDa (black arrow).




**Figure S2. Preliminary SPCE tests to select representative bovine scFv clones.** Binding of biotin-labeled, O type-specific (A) and pan-serotype specific (B) scFvs to FMDV type O antigen (O1 Manisa) in the presence of 1/10 dilution of respective serum was detected using NA-HRP. The test serum samples were derived from vaccinated cattle and FMDV (O/Anseong/SKR/2002)-challenged pigs. One hundred percent binding corresponds to the value of absorbance obtained in the presence of FBS.


**A**



**B**



**Figure S3. Bovine scFv antibody-based SPCE using positive control anti-sera for seven serotypes of FMDV.** (A, D) PrioCHECK FMDV type O and A antibody ELISA kits were used for comparison. The control sera purchased from Pirbright Insti-tute were diluted and tested following manufacturer's instruction. (B, C) Binding of biotin-labeled BvO17 or BvOA7 to FMDV type O antigen (O1 Manisa) in the presence of 1/10 dilution of respective control serum was detected using NA-HRP. (E, F) Binding of BvA3 or biotin-labeled BvOA7 to FMDV type A antigen (A22 Iraq) in the presence of 1/10 dilution of respective control serum was detected using HRP-conjugated anti-human IgG or NA-HRP, respectively. For all the SPCE experiments, the serum samples were tested in triplicate. One hundred percent binding corresponds to the value of absorbance obtained in the presence of negative control serum.



**Table S1. Primer sets for bovine antibody library construction.**

<b>BVH Forward primer</b>	<b>Sequences (5'-3')</b>
BVH1-2	5'-GCGGCCAGCCGGCCATGGCCCAGGTGCAGCTGCGGGAGTC-3'
BVH1Q	5'-GCGGCCAGCCGGCCATGGCCCAGGTGCAGCTGCAGGAGTC-3'
BVH1K	5'-GCGGCCAGCCGGCCATGGCCAAGGTGCAGCTGCAGGAGTC-3'
<b>BJH Reverse primer</b>	<b>Sequences (5'-3')</b>
BJH1R	5'-CGAGCCGCCGCCAGATCCACCTCCACCTGAACCTCCTCCACCTGAGGAGACGGTGACCAGG-3'
BJH2R	5'-CGAGCCGCCGCCAGATCCACCTCCACCTGAACCTCCTCCACCTGAGGAGACGGTGACCTCG-3'
BJH6R	5'-CGAGCCGCCGCCAGATCCACCTCCACCTGAACCTCCTCCACCTGAGGAGACGGTGACCCTG-3'
<b>BVk Forward primer</b>	<b>Sequences (5'-3')</b>
BVk2	5'-GGATCTGGCGGCGGCGGCTCGGATGTTGTGCTGACCCAGAC-3'
BVk4	5'-GGATCTGGCGGCGGCGGCTCGGACATCCAGGTGACCCAGTC-3'
<b>BJk Reverse primer</b>	<b>Sequences (5'-3')</b>
BJk1R	5'-CTGCTCGAGGCCTCCCGGGCCTTTGATCTCTACCTTGGTTCC-3'
<b>BVλ Forward primer</b>	<b>Sequences (5'-3')</b>
BVλ1	5'-GGATCTGGCGGCGGCGGCTCGCAGGCTGTGCTGACTCAGC-3'
BVλ1-6	5'-GGATCTGGCGGCGGCGGCTCGCAGGATGTGCTGACTCAGC-3'
BVλ2	5'-GGATCTGGCGGCGGCGGCTCGCAGTCTGGCCTGACTCAGC-3'
BVλ6-14	5'-GGATCTGGCGGCGGCGGCTCGTCTTCTCAGCTGACTCAGC-3'
BVλ6-156	5'-GGATCTGGCGGCGGCGGCTCGTCCTATGAACTGACCCAG-3'
BVλ7-21	5'-GGATCTGGCGGCGGCGGCTCGCAGCCTGTGCTGACTCAGC-3'
BVλ8-40	5'-GGATCTGGCGGCGGCGGCTCGCAGACTGTGATCCAGGAAC-3'
<b>BJλ Reverse primer</b>	<b>Sequences (5'-3')</b>
BJλ2R	5'-CTGCTCGAGGCCTCCCGGGCCCAGGACGGTCACTCTGGTCC-3'
BJλ3R	5'-CTGCTCGAGGCCTCCCGGGCCCAGGACGGTCAGTGTGGTCC-3'
<b>VH Forward extension primer scFv assembly</b>	<b>Sequences (5'-3')</b>
scFv-Fex	5'-GACGACGACGACGACGCGGCCAGCCGGCCATGGCC-3'
<b>VL Reverse extension primer scFv assembly</b>	<b>Sequences (5'-3')</b>
scFv-Rex	5'-GACGACGACGACGACCTGCTCGAGGCCTCCCGGGCC-3'